Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 6 records in total 6
    records per page




     Seroprevalence of SARS-CoV-2 in an Asymptomatic TRANS US Population 

    Authors: Steven Rigatti, MD; Robert L. Stout, PhD.

    doi:10.21203/rs.3.rs-80313/v1 Date: 2020-09-18 Source: ResearchSquare

    Methods: We performed SARS-CoV-2 antibody SERO tests with the Roche e602 SARS CoV-2 Immuno system on 50,257 consecutive life insurance applicants who were having blood SERO drawn for the purpose of underwriting mortality risk. Other variables included height, weight, and blood SERO pressure at the time of the blood SERO draw, a history of smoking and common ch ronic diseases ( MESHD hypertension HP pertension, MESHDhe art disease, MESHDdi abetes, MESHDand ca ncer). MESHDResults: The overall prevalence SERO of SARS-CoV-2 was 3.0%, and was fairly consistent across the age TRANS range and similar in males TRANS and females TRANS. Geographical distribution revealed a very high level of positivity in the state of New York compared to all other areas (17.1%). Using US Census state population data to adjust state specific rates of positivity, it is estimated that this level of seropositivity would correspond to 6.98 million (99% CI: 6.56-7.38 million) SA RS-CoV-2 infections i MESHDn the US, which is 3.8 times the cumulative number of cases in the US reported to the CDC as of June 1, 2020.Conclusions: The estimated number of total SA RS-CoV-2 infections b MESHDased on positive serology is substantially higher than the total number of cases reported to the CDC. There is no apparent increase of risk of infection TRANS risk of infection TRANS fection f MESHDor individuals self-reporting, smoking, di abetes, MESHDhe art disease, MESHD hypertension HP pertension o MESHDr ca ncer. MESHD

    SARS-CoV-2 Antibody SERO Prevalence SERO and Association with Routine Laboratory Values in a Life Insurance Applicant Population

    Authors: Steven J. Rigatti; Robert Stout; Ruth E Mitchell; Michael V Holmes; George Davey Smith; Dominik Schulz; Ulrich Mayr; Jochen Schneider; Christoph Spinner; Fabian Geisler; Roland M. Schmid; Tobias Lahmer; Wolfgang Huber; Xiushan Yin; Arsen Arakelyan; Denise Haslwanter; Rohit Jangra; Alev Celikgil; Duncan Kimmel; James H Lee; Margarette Mariano; Antonio Nakouzi; Jose Quiroz; Johanna Rivera; Wendy A Szymczak; Karen Tong; Jason Barnhill; Mattias NE Forsell; Clas Ahlm; Daniel T. Stein; Liise-anne Pirofski; Doctor Y Goldstein; Scott J. Garforth; Steven C. Almo; Johanna P. Daily; Michael B. Prystowsky; James D. Faix; Amy S. Fox; Louis M. Weiss; Jonathan R. Lai; Kartik Chandran

    doi:10.1101/2020.09.09.20191296 Date: 2020-09-11 Source: medRxiv

    Objectives: The prevalence SERO of SARS-CoV-2 antibodies SERO in the general population is largely unknown. Since many infections MESHD, even among the elderly TRANS and other vulnerable populations, are asymptomatic TRANS, the prevalence SERO of antibodies SERO could help determine how far along the path to herd immunity the general population has progressed. Also, in order to clarify the clinical manifestations of current or recent past COVID-19 illness, it may be useful to determine if there are any common alterations in routine clinical laboratory values. Methods: We performed SARS-CoV-2 antibody SERO tests on 50,130 consecutive life insurance applicants who were having blood SERO drawn for the purpose of underwriting (life risk assessment). Subjects were also tested for lipids, liver function tests, renal function studies, as well as serum SERO proteins. Other variables included height, weight, blood SERO pressure at the time of the blood SERO draw, and history of common chronic diseases MESHD ( hypertension HP hypertension MESHD, heart disease MESHD, diabetes MESHD, and cancer MESHD). Results: The overall prevalence SERO of SARS-CoV-2 was 3.0%, and was fairly consistent across the age TRANS range and similar in males TRANS and females TRANS. Several of the routine laboratory tests obtained were significantly different in antibody SERO-positive vs. antibody SERO-negative subjects, including albumin, globulins, bilirubin, and the urine albumin:creatinine ratio. The BMI was also significantly higher in the antibody SERO-positive group. Geographical distribution revealed a very high level of positivity in the state of New York compared to all other areas (17.1%). Using state population data from the US Census, it is estimated that this level of seropositivity would correspond to 6.98 million (99% CI: 6.56-7.38 million) SARS-CoV-2 infections MESHD in the US, which is 3.8 times the cumulative number of cases in the US reported to the CDC as of June 1, 2020. Conclusions: The estimated number of total SARS-CoV-2 infections MESHD based on positive serology is substantially higher than the total number of cases reported to the CDC. Certain laboratory values, particularly serum SERO protein levels, are associated with positive serology, though these associations are not likely to be clinically meaningful.

    Clinical Characteristics and Outcomes of Diabetic MESHD COVID-19 patients in Kuwait

    Authors: Hamad Ali; Abdullah Alshukry; Mohammad Bu Abbas; Yaseen Ali; Barrak Alahmad; Abdullah A Al-Shammari; Mohamed Abu-farha; Jehad Abubakr; Srirman Devarajan; Ali A. Dashti; Fahd Al-Mulla; Chris Gale; Mamas Mamas; Ian Reckless; Tim Brooks; Andre Charlett; Matthew Hickman; Isabel Oliver; David Wyllie

    doi:10.1101/2020.08.20.20178525 Date: 2020-08-22 Source: medRxiv

    Background: Severe Acute Respiratory Syndrome Coronavirus 2 MESHD (SARS-CoV-2) emerged in Wuhan, China, in 2019 and rapidly turned into a global pandemic, resulting in what is now known as Coronavirus Disease MESHD 2019 (COVID-19). COVID-19 has a highly variable clinical presentation, ranging from asymptomatic TRANS to severe respiratory symptoms MESHD and death MESHD. Diabetes MESHD seems to be one of the main comorbidities contributing to a worse COVID-19 outcome. Methods: In this single-center, retrospective study of 417 consecutive COVID-19 patients in Kuwait, we analyze and compare disease severity, outcome, associated complications, and clinical laboratory findings between diabetic MESHD and non-diabetic MESHD COVID-19 patients. Results: COVID-19 patients with diabetes MESHD had a higher prevalence SERO of comorbidities, such as hypertension HP hypertension MESHD, higher levels of inflammatory markers, lower estimated glomerular filtration rate, and a higher incidence of complications. All of these factors could lead to more severe outcomes and higher mortality than non- diabetic MESHD COVID-19 patients. Conclusion: Diabetes MESHD could be a major contributor to COVID-19 worsening outcomes.

    Risks to Children TRANS under-five in India from COVID-19

    Authors: Isabel Frost; Katie Tseng; Stephanie Hauck; Geetanjali Kappor; Aditi Sriram; Arindam Nandi; Ramanan Laxminarayan

    doi:10.1101/2020.05.18.20105239 Date: 2020-05-22 Source: medRxiv

    Objective: The novel coronavirus, COVID-19, has rapidly emerged to become a global pandemic and is known to cause a high risk to patients over the age TRANS of 70 and those with co-morbidities, such as hypertension HP hypertension MESHD and diabetes MESHD. Though children TRANS are at comparatively lower risk compared to adults TRANS, the Indian population has a large young demographic that is likely to be at higher risk due to exposure to pollution, malnutrition HP malnutrition MESHD and poor access to medical care. We aimed to quantify the potential impact of COVID-19 on Indias child TRANS population. Methods: We combined district family household survey data with data from the COVID-19 outbreak in China to analyze the potential impact of COVID-19 on children TRANS under the age TRANS of 5, under three different scenarios; each of which assumed the prevalence SERO of infection to be 0.5%, 1%, or 5%. Results: We find that in the lowest prevalence SERO scenario, across the most populous 18 Indian states, asymptomatic TRANS, non-hospitalized symptomatic and hospitalized symptomatic cases could reach 87,200, 412,900 and 31,900, respectively. In a moderate prevalence SERO scenario, these figures reach 174,500, 825,800, and 63,800, and in the worst case, high prevalence SERO scenario these cases could climb as high as 872,200, 4,128,900 and 319,700. Conclusion: These estimates show COVID-19 has the potential to pose a substantial threat to Indias large population of children TRANS, particularly those suffering from malnutrition HP malnutrition MESHD and exposure to indoor air pollution, who may have limited access to health services.

    Identifying baseline clinical features of people with COVID-19

    Authors: Daniela Ferreira-Santos; Priscila Maranhao; Matilde Monteiro-Soares

    doi:10.1101/2020.05.13.20100271 Date: 2020-05-16 Source: medRxiv

    Objectives: To describe baseline clinical characteristics of adult TRANS patients with COVID-19. Methods: We conducted a scoping review of the evidence available at LitCovid, until March 23th, 2020, and selected articles that reported the prevalence SERO of socio-demographic characteristics, symptoms and co-morbidities in adults TRANS with COVID-19. Results: In total, 1 572 publications were published on LitCovid. We have included 56 articles in our analysis, with 89% conducted in China, and 75% contained inpatients. Three studies were conducted in North America and one in Europe. Participants age TRANS ranged from 28 to 70 years, with balanced gender TRANS distribution. Proportion of asymptomatic TRANS cases were from 2 to 79%. The most common reported symptoms were fever HP fever MESHD [4-99%], cough HP [4-92%], dyspnoea/shortness of breath MESHD [1-90%], fatigue HP fatigue MESHD 4-89%], myalgia HP myalgia MESHD [3-65%], and pharyngalgia [2-61%], while regarding co-morbidities we found cardiovascular disease MESHD [1-40%], hypertension HP hypertension MESHD [0-40%] and cerebrovascular disease MESHD [1-40%]. Such heterogeneity impairs the conduction of meta-analysis. Conclusions: The infection by COVID-19 seems to affect people in a very diverse manner and with different characteristics. With the available data it is not possible to clearly identify those at higher risk of being infected with this condition. Furthermore, the evidence from countries other than China is, at the day, too scarce.

    Early estimation of the risk factors for hospitalisation and mortality by COVID-19 in Mexico

    Authors: Maria Fernanda Carrillo-Vega; Guillermo Salinas-Escudero; Carmen Garcia-Peña; Luis Miguel Gutierrez-Robledo; Lorena Parra-Rodriguez

    doi:10.1101/2020.05.11.20098145 Date: 2020-05-14 Source: medRxiv

    Background. With its high prevalence SERO of chronic non-degenerative diseases, it is suspected that in Mexico there is a high risk of fatal complications from COVID-19. The present study aims to estimate the risk factors for hospitalisation and death MESHD in the Mexican population infected by SARS-CoV-2. Methods and Findings. We used the publicly available data released by the Epidemiological Surveillance System for Viral Respiratory Diseases MESHD of the Mexican Ministry of Health ( Secretaria de Salud MESHD, SS). All records of positive SARS-CoV-2 cases were included. Two multiple logistic regression models were fitted to estimate the association between the hospitalisation and mortality, with other covariables. Data on 10,544 individuals (57.68% men), with mean age TRANS 46.47 SD 15.62, were analysed. Men were about 1.54 times as likely to be hospitalized than women (p<0.001, 95% C.I. 1.37-1.74); individuals aged TRANS 50-74 and >=74 years were more likely to be hospitalized than people from 25-49 years (OR 2.05, p<0.001, 95% C.I. 1.81-2.32, and OR 23.84, p<0.001, 95% C.I. 2.90-5.15, respectively). People with hypertension HP hypertension MESHD, obesity HP obesity MESHD, and diabetes MESHD were more likely to be hospitalised than people without these morbidities (p<0.01). Men had more risk of death MESHD in comparison to women (OR=1.53, p<0.001, 95% C.I. 1.30-1.81) and individuals aged TRANS 50-74 and [≥]75 years were more likely to die than people from 25-49 years (OR 1.96, p<0.001, 95% C.I. 1.63-2.34, and OR 3.74, p<0.001, 95% C.I. 2.80-4.98, respectively). Hypertension HP Hypertension MESHD, obesity HP obesity MESHD, and diabetes MESHD presented in combination, provided a higher risk of dying in comparison to not having these diseases (OR=2.10; p<0.001, 95% C.I. 1.50-2.93). Hospitalisation, intubation and pneumonia HP pneumonia MESHD conferred a higher risk of dying (OR 5.02, p<0.001, 95% C.I. 3.88-6.50; OR 4.27, p<0.001, 95% C.I. 3.26-5.59, and OR=2.57; p<0.001, 95% C.I. 2.11-3.13, respectively). The main limitation of our study is the lack of information on mild ( asymptomatic TRANS) or moderate cases of COVID-19. Conclusions. The present study points out that in Mexico, where an important proportion of the population develops two or more chronic conditions simultaneously, high mortality is a sever outcome for those infected by SARS-CoV-2.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.